Adial Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ADIL Nasdaq 2834 www.adial.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045 - Jan 14th, 2026 7:00 am
Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year? - Jan 6th, 2026 7:40 am
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds - Nov 26th, 2025 6:00 am
Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - Nov 14th, 2025 6:30 am
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show - Oct 17th, 2025 7:00 am
Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution - Oct 9th, 2025 6:30 am
CoreWeave initiated, Instacart downgraded: Wall Street's top analyst calls - Sep 30th, 2025 7:42 am
Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder - Sep 16th, 2025 6:03 am
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04 - Sep 16th, 2025 6:00 am
Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule - Sep 3rd, 2025 6:30 am
All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy - Sep 1st, 2025 10:00 am
Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments - Aug 20th, 2025 6:30 am
Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - Aug 14th, 2025 6:30 am
Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting - Aug 6th, 2025 6:00 am
Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement - Jul 16th, 2025 6:30 am
Thermo Fisher Scientific (TMO) Inks Deal to Manufacture Adial Pharmaceuticals ADO4 - Jul 15th, 2025 7:10 am
Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why - Jul 10th, 2025 10:00 am
Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045 - Jul 9th, 2025 6:30 am
Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck - Jul 9th, 2025 4:15 am
Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply - Jun 25th, 2025 6:30 am